NexImmune, Inc. Multiple Myeloma Research Foundation (MMRF) Venture Philanthropy Fund Invests in NexImmune to Advance Novel Immunotherapy Candidate Into Clinical Trials Partnership yields the first investment from newly launched MMRF…
Read More
Read news items items specific to Ponce Therapeutics or about other Rapha Capital-related entities. Also see scientific articles detailing the rapid advances in the important science of anti-aging
News
Poseida Therapeutics and Rapha Capital Management Rapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals April 22, 2019
Poseida Therapeutics Poseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round April 22, 2019
3DBio Therapeutics 3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors April 1, 2019
AsclepiX Therapeutics AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven Altschuler, MD AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease…
AsclepiX Therapeutics AXT107 Restores Healthy, Non-Leaky Vasculature in the Eye by Inhibiting VEGFR2 and Activating Tie2, the Two Clinically Validated Pathways in Diseases of the Retina AXT107 exhibited a dual…